The DOI matches its Crossref record; 164 of the 164 references it cites were found in a registry or an index.
Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care
Open accessAbstract
Ongoing research into the application of nanotechnology for cancer treatment and diagnosis has demonstrated its advantages within contemporary oncology as well as its intrinsic limitations. The National Cancer Institute publishes the Cancer Nanotechnology Plan every 5 years since 2005. The most recent iteration helped codify the ongoing basic and translational efforts of the field and displayed its breadth with several evolving areas. From merely a technological perspective, this field has seen tremendous growth and success. However, an incomplete understanding of human cancer biology persists relative to the application of nanoscale materials within contemporary oncology. As such, this review presents several evolving areas in cancer nanotechnology in order to identify key clinical and biological challenges that need to be addressed to improve patient outcomes. From this clinical perspective, a sampling of the nano-enabled solutions attempting to overcome barriers faced by traditional therapeutics and diagnostics in the clinical setting are discussed. Finally, a strategic outlook of the future is discussed to highlight the need for next-generation cancer nanotechnology tools designed to address critical gaps in clinical cancer care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
Structure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Cited by
Reactive Oxygen Species (ROS)-Based Nanomedicine
Yang, B., Chen, Y., & Shi, J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00626 · Cited by 2,443
Nanomaterials for cancer therapy: current progress and perspectives
Cheng, Z., Li, M., Dey, R., & Chen, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01096-0 · Cited by 1,168
A review on graphene-based nanocomposites for electrochemical and fluorescent biosensors
Krishnan, S. K., Singh, E., Singh, P., Meyyappan, M., & Nalwa, H. S. (2019) · RSC Advances · doi:10.1039/c8ra09577a · Cited by 785
Emerging Applications of Nanotechnology in Healthcare and Medicine
Malik, S., Muhammad, K., & Waheed, Y. (2023) · Molecules · doi:10.3390/molecules28186624 · Cited by 610
Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies
Soetaert, F., Korangath, P., Serantes, D., Fiering, S., & Ivkov, R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.025 · Cited by 406
Yan, R., Hu, Y., Liu, F., Wei, S., Fang, D., Shuhendler, A. J., Liu, H., Chen, H.-Y., & Ye, D. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b03649 · Cited by 389
Zhang, X., Li, G., Wu, D., Li, X., Hu, N., Chen, J., Chen, G., & Wu, Y. (2019) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2019.04.061 · Cited by 379
Pokrajac, L., Abbas, A., Chrzanowski, W., Dias, G. M., Eggleton, B. J., Maguire, S., Maine, E., Malloy, T., Nathwani, J., Nazar, L., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c10919 · Cited by 365
Nanoparticles in cancer theragnostic and drug delivery: A comprehensive review
Al-Thani, A. N., Jan, A. G., Abbas, M., Geetha, M., & Sadasivuni, K. K. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122899 · Cited by 323
Organic Dye Based Nanoparticles for Cancer Phototheranostics
Cai, Y., Si, W., Huang, W., Chen, P., Shao, J., & Dong, X. (2018) · Small · doi:10.1002/smll.201704247 · Cited by 306
Advanced hybrid nanomaterials for biomedical applications
Park, W., Shin, H., Choi, B., Rhim, W.-K., Na, K., & Keun Han, D. (2020) · Progress in Materials Science · doi:10.1016/j.pmatsci.2020.100686 · Cited by 299
Janus Nanoparticles: From Fabrication to (Bio)Applications
Zhang, X., Fu, Q., Duan, H., Song, J., & Yang, H. (2021) · ACS Nano · doi:10.1021/acsnano.1c01146 · Cited by 286
Fang, F., Wang, S., Song, Y., Sun, M., Chen, W.-C., Zhao, D., & Zhang, J. (2023) · Nature Communications · doi:10.1038/s41467-023-37315-0 · Cited by 112
Gupta, P. K., Gupta, S., Pappuru, S., Chabattula, S. C., Chakraborty, D., & Verma, R. S. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.02.022 · Cited by 12
Metadata
- Authors
- Hartshorn, C. M., Bradbury, M. S., Lanza, G. M., Nel, A. E., Rao, J., Wang, A. Z., Wiesner, U. B., Yang, L., & Grodzinski, P.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-12-22
- Volume
- 12
- Issue
- 1
- Pages
- 24-43
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2777643352
- Cited by
- 258
- References
- 164
- FWCI
- 8.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.